To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
TIAP, Evotec, AmorChem invest in Sinai Health newborn skin disease project
Toronto Innovation Acceleration Partners, Evotec SE and Canadian life sciences venture capital firm AmorChem have together invested C$1.75 million in the Netherton Syndrome project at Toronto-based Sinai Health.
